key: cord-0724198-qmqocq34
authors: Bi, Xiaojie; Liu, Wei; Ding, Xuan; Liang, Shuang; Zheng, Yufen; Zhu, Xiaoli; Quan, Sheng; Yi, Xiao; Xiang, Nan; Du, Juping; Lyu, Haiyan; Yu, Die; Zhang, Chao; Xu, Luang; Ge, Weigang; Zhan, Xinke; He, Jiale; Xiong, Zi; Zhang, Shun; Li, Yanchang; Xu, Ping; Zhu, Guangjun; Wang, Donglian; Zhu, Hongguo; Chen, Shiyong; Li, Jun; Zhao, Haihong; Zhu, Yi; Liu, Huafen; Xu, Jiaqin; Shen, Bo; Guo, Tiannan
title: Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19
date: 2021-12-28
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.110271
sha: 02810e43e27d8c1eeeef4b179fc82dcd3bf8e14b
doc_id: 724198
cord_uid: qmqocq34

The utility of the urinary proteome in infectious diseases remains unclear. Here we analyzed the proteome and metabolome of urine and serum samples from patients with COVID-19 and healthy controls. Our data show that urinary proteins effectively classify COVID-19 by severity. We detect 197 cytokines and their receptors in urine but only 124 in serum using TMT-based proteomics. Decrease of urinary ESCRT complex proteins correlates with active SARS-CoV-2 replication. Downregulation of urinary CXCL14 in severe COVID-19 cases positively correlates with blood lymphocyte counts. Integrative multiomic analysis suggests that innate immune activation and inflammation triggered renal injuries in patients with COVID-19. COVID-19-associated modulation of the urinary proteome offers unique insights into the pathogenesis of this disease. This study demonstrates the added value of including the urinary proteome in a suite of multiomic analytes in evaluating the immune pathobiology and clinical course of COVID-19 and, potentially, other infectious diseases.

CCL 25 CX CL 14 P P B P C X C L 1 2 C X 3 C L 1 C C L 1 4 C X C L 1 6 C C L 1 6 P F 4 C C L 5 C C L 1 8 C C L 1 5 IL 1 R N IL 1 8 IL 3 4 GD F1 5 TG FB 1 T N F S F 1 3 T N F S F 8 T N F S F 1 3 B cases with flu-like symptoms such as cough and fever, and 27 healthy 108 controls were enrolled as controls ( Figure 1A ; Table 1; Table S1 ). Age and (Table S1 ; Figure S1A , B, C). In addition, 106 urine samples (Table   116 S1; Figure S1C ).

Peptide yields from serum samples were not significantly different among 118 the four groups (healthy, non-COVID-19, non-severe, and severe), indicating 119 reproducibility of our sample preparation method ( Figure 1B ). However, 120 peptide yields from urine specimens were significantly higher in severe and 121 non-severe cases than from healthy controls ( Figure 1B ). This observation 122 confirms a report of proteinuria in patients infected with SARS-CoV-2 (Su et   123 al., 2020). 124 We identified and quantified 16,148 peptides and 1494 proteins from sera 125 using TMT-based proteomics, while 19,732 peptides and 3854 proteins were 126 identified from urine using similar methodology (Methods , Table S2 ; Figure   127 1C, D). The proteomic depth of urine specimens achieved in this study 128 exceeds most other published studies (Table S3) , and is reasonably deep to 129 encompass most urinary proteins. Moreover, we characterized 1033 urine 130 metabolites and 903 serum metabolites in patients with COVID-19 (Table S2; 131 Figure 1E ). The serum and urine proteome data set showed minimal batch 132 effects ( Figure S1D , E). The median coefficients of variance (CV) of the 133 quality control (QC) samples were 13% for proteomic data and 3.5% for 134 metabolomic data, indicating robust quality of our data ( Figure 1F ). showed that the numbers of quantified metabolites in sera and urine are 143 similar ( Figure 1E , 903 vs.1033). Unlike proteins however, 62% of serum 144 metabolites, i.e. 557 metabolites, were detectable in urine ( Figure 1E ). The 145 discrepancy in protein and metabolite detection is probably due to differences 146 in their abundance and stability in sera and urine.

It is generally assumed that the molecular weight (MW) cutoff for structure organization related to biological processes ( Figure 2D ). We further 183 explored the power for classifying severity of these top 20 urinary proteins 184 compared to that for sera. By increasing the number of proteins in the model, 185 we optimized 20 random forest models for each specimen type and evaluated 186 the performance of the respective classifier in terms of accuracy and area 187 under curve (AUC) after internal cross-validation, as detailed in Methods. Our 188 data showed that urine-derived models performed equally well as those from 189 sera ( Figure 2E ). As the number of features in the model exceeded the top 190 four, the accuracy of the models for both sample types rose beyond 0.9, and 191 the AUC was higher than 0.95 ( Figure 2E ).

To further evaluate the performance of such urinary proteins for 193 classifying COVID-19 severity, we trained a model using the 20 urinary 194 proteins above and tested it on an independent TMT-labelled urinary 195 proteomic data set of 13 patients with COVID-19 (Table S2) Figure 2F ). These data further support the utility of our urinary protein model 205 for predicting progression to clinical severity in early infection.

Taken together, our data showed that urinary proteomics can be as 207 informative as that of sera in terms of classifying and predicting COVID-19 208 severity. Considering its non-invasive nature and easy accessibility, urine 209 could be a widely used sample source for COVID-19 management.

Nevertheless, more independent validation is required before this could 211 become clinical standard of care. 

Cytokines produced by immune cells mediate diverse immune processes. Table S4 ).

The dysregulated proteins in serum were enriched in 23 pathways and 323 those in urine in 108 pathways. Interestingly, 20 pathways from the serum 324 data also appeared in the urine data ( Figure 4C ; Table S5 ), suggesting that 

364

The dysregulated metabolites in COVID-19 urine and serum were 365 enriched in ten KEGG pathways (Table S5) , including tryptophan biosynthesis 366 and metabolism ( Figure 4E ; Table S5 ). There are three metabolic pathways produce more quinolinate after an inflammatory response (Heyes, 1993) .

Taken as a whole, the metabolomic data point to widely activated ROS 406 production which could lead to a variety of immune-mediated tissue injury in 407 patients with COVID-19.

Inflammation induced renal injuries as revealed by multiomics data 409 The 20 pathways prominent in both serum and urine were mainly related 410 to immunity (Table S6) . We found most immunity related pathways were 411 downregulated in urine but upregulated in serum, except for protein kinase A 412 signaling, coagulation system, acute phase response signaling, and LXR/RXR 413 activation, which were upregulated in both serum and urine (Table S6) .

Protein kinase A signaling was reported to be involved in the innate immunity (Table S5) , the 427 leukocyte extravasation signaling pathway stood out for its activation level (Z 428 score 2.6) ( Figure 5A ; Table S5 ). Vascular cell adhesion protein 1 (VCAM-1) 429 and intercellular adhesion molecule 1 (ICAM-1), which participate in leukocyte Figure S1I , Figure S2H and Figure S6B ). LRP2 and CDC42 also 514 showed a declining trend, though not statistically significant. ELISA showed 515 similar results, but did not achieve statistical significance ( Figure S1I ). This 516 may be because ELISA is an antibody-based chromogenic reaction whose 517 performance is crucially dependent on antibody quality (sensitivity and In this study, about 35% non-COVID-19 cases and 37% patients with 533 COVID-19 had comorbidities such as hypertension and diabetes (Table 1) . 534 We cannot completely exclude effects of comorbidities on changes in the 535 proteomic or metabolomic data. However, we took care to ensure that COVID- In this study, patients scored as 3 or 4 were defined as non-severe patients, 689 and patients scored as score 5 or 6 were defined as severe patients (Table   690   S1 ). We also included 17 non-COVID-19 cases, who had clinical symptoms 691 similar to COVID-19, including fever and/or cough, but the nucleic acid test antibiotics (Table 1) .

The fasting venous blood and the first-morning midstream urine of all 701 subjects were collected in the morning. The venous blood samples were 1% target false discovery rate (FDR).

The protein abundance ratios of target samples to the pooled sample 818 within each batch were used as the relative protein abundance for data 819 analysis.

For metabolomics data analysis, metabolites were identified by searching 821 an in-house library of more than 3,300 standards whose data entries are Mfuzz analysis, we selected 148 DEPs in clusters 1, 2, 3 and 4 ( Figure S4B ) 873 and 161 DEMs in cluster 1, 3, 6 and 7 ( Figure S4D ) for further pathway 874 enrichment analysis. For urine, we selected 580 DEPs in clusters 1, 3, 5, 6 875 and 7 ( Figure S4C ) and 138 DEMs in clusters 2, 6 and 8 for further pathway 876 enrichment analysis ( Figure S4E ).

Machine learning 879 An R package RandomForest (version 4.6.14) was used to select SHH  CR2  AGT  MRC1  RNASE4  IGFBP2  ALB  IL6R  VSIG4  TKT  IL1R2  IGFBP3  LEAP2  VWF  SERPINA3  F9  APMAP  FBLN5  SAA1  IGF1   5  7  9 11  MeanDecreaseAccuracy   Top 20 features in serum   Top 20 features in urine   BTNL3  CD84  SPOCK1  RHDE  CDH19  CDH22  MADCAM1  SERPINI1  PRSS2  MELTF  NPR3  ICOSLG  OSTN  ADGRL1  MLEC  PTGFRN  TNR  FREM2  CEL  VPS36   5  6  7  8  MeanDecreaseAccuracy   SAA1  IL6R  SERPINA3  TKT  VWF  MRC1  APMAP  IL1R2  AGT  F9  LEAP2  RNASE4  IGFBP2  FBLN5  VSIG4  ALB  SHH  CR2  IGFBP3 SERPINI1  CDH19  ICOSLG  TRHDE  NPR3  FREM2  PTGFRN  ADGRL1  CEL  MADCAM1  SPOCK1  MELTF  VPS36  BTNL3  CDH22  CD84  OSTN  TNR CCL2 5 CX CL 14 P P B P C X C L 1 2 C X 3 C L 1 C C L 1 4 C X C L 1 6 C C L 1 6 P F 4 C C L 5 C C L 1 8 E   TSG101  VPS28  VPS37D  VPS36  SNF8  VPS25  CHMP2A  CHMP3  CHMP4A  CHMP4B  CHMP4C  CHMP5  CHMP1B  LRSAM1  VPS4A  VPS4B  PDCD6IP  VTA1   Group   Sex   Age   TSG101  VPS28  VPS37D  VPS25  CHMP2A  CHMP3  CHMP4A  CHMP4B  CHMP4C  CHMP5  CHMP1B  LRSAM1  VPS4A  VPS4B  PDCD6IP Highlights  More cytokines and their receptors are detected in urine than in serum  Machine learning models based on urinary proteins equal the ones using sera proteins  Dysregulated inflammatory processes induce renal injury as revealed by multiomics data

The value of the urine proteome is largely underestimated compared to the blood proteome. Bi et al. systematically compare proteins and metabolites in COVID-19 urine and sera, and show the urine proteome to be a valuable source of biomarkers, offering unique insights into the pathogenesis of infectious diseases.

The human urinary

Coronavirus and PARP 1007 expression dysregulate the NAD Metabolome: a potentially actionable component of 1008 innate immunity

Quinolinic acid and inflammation

Membrane budding and scission by the ESCRT 1012 machinery: it's all in the neck

Podocyte energy metabolism and glomerular 1014 diseases

Gene Summary

An update of urine and blood metabolomics in 1017 chronic kidney disease

Evaluation of Coronavirus 1020 Disease 2019 Severity Using Urine Biomarkers

Causal analysis 1022 approaches in Ingenuity Pathway Analysis

Plasma and urinary 1026 levels of adrenomedullin in chronic glomerulonephritis patients with proteinuria

Mfuzz: a software package for soft clustering 1029 of microarray data

The seven amino acids of human RAMP2 (86) and RAMP3 (59) are 1032 critical for agonist binding to human adrenomedullin receptors

Immune-centric network of cytokines and cells in disease context identified by 1037 computational mining of PubMed

Taurine and hypotaurine content 1039 of human leukocytes

Sphingosine-1-phosphate reduces hepatic ischaemia/reperfusion-induced acute 1042 kidney injury through attenuation of endothelial injury in mice

Inflammation and coagulation

Urinary epidermal growth factor as a prognostic marker 1048 for the progression of Alport syndrome in children

Urine proteome of COVID-19 patients

Quinolinic Acid: An Endogenous Neurotoxin with Multiple 1055

The beneficial role of retinoids in glomerular 1057 disease

Taurine and inflammatory diseases

UMAP: Uniform Manifold Approximation 1061 and Projection for Dimension Reduction

Clinical Proteomics Reveals Classifiers of COVID-19 Infection

Urinary cAMP activity in chronic renal 1067 failure

Getting leukocytes to the site of inflammation

Advancing Urinary Protein Biomarker Discovery by Data-Independent 1072

Orbitrap Mass Spectrometer

Urinary megalin deficiency 1076 implicates abnormal tubular endocytic function in Fanconi syndrome

COVID-19 infection and oxidative stress: an under-explored

Podocyte-actin dynamics 1092 in health and disease

Dysregulation of immune response in patients with 1095 COVID-19 in Wuhan, China

Networking Rho family GTPases in lymphocytes

Acute kidney injury

The value of urine biochemical parameters in the prediction 1102 of the severity of coronavirus disease 2019

Podocyte RhoGTPases: new therapeutic targets 1105 for nephrotic syndrome?

Rho-GTPases as key regulators 1107 of T lymphocyte biology

Expression of interleukin 6 in the rat striatum following stereotaxic 1110 injection of quinolinic acid

Coagulation factor V and 1116 thrombophilia: background and mechanisms

Proteomic and Metabolomic Characterization of COVID-19

Inhibition of TGF-β1-receptor posttranslational core fucosylation 1122 attenuates rat renal interstitial fibrosis

N-Acetylcysteine to Combat COVID-19: An Evidence 1124

The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase 1130 complex to control autophagy

Renal histopathological analysis of 26 postmortem 1134 findings of patients with COVID-19 in China

Links between coagulation, 1137 inflammation, regeneration, and fibrosis in kidney pathology

Lymphopenia predicts disease severity of COVID-19: a descriptive and 1141 predictive study

COVID-19 1144 infection results in alterations of the kynurenine pathway and fatty acid metabolism 1145 that correlate with IL-6 levels and renal status

Immune suppression in the early stage of COVID-19 disease

Urinary proteome profiling for 1152 stratifying patients with familial Parkinson's disease

Urinary cyclic AMP and post-traumatic acute renal failure

Characterizing 1159 Patients with Recurrent Urinary Tract Infections in Vesicoureteral Reflux: A Pilot 1160 Study of the Urinary Proteome

Chorionic gonadotropin can enhance innate immunity by 1164 stimulating macrophage function

Report of the WHO-China Joint Mission on Coronavirus Disease

Coronavirus Updates

Ephrins and Eph Receptor 1171

Signaling in Tissue Repair and Fibrosis